Evidence map›Paper›PMID 31660687›Full record

ArticleCancer science2020

Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.

Ken Imaizumi, Toshihiro Suzuki, Motohiro Kojima, Manami Shimomura, Naoki Sakuyama, Yuichiro Tsukada, Takeshi Sasaki, Yuji Nishizawa, Akinobu Taketomi, Masaaki Ito and 1 more

Abstract read
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Increased Infiltration of CD4Cancer reports (Hoboken, N.J.) · 2026
    Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Prognostic role of proliferating CD8Cellular oncology (Dordrecht, Netherlands) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ken ImaizumiDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-7751-6270
Toshihiro SuzukiDivision of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-7095-6556
Motohiro KojimaDivision of Pathology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-6150-6545
Manami ShimomuraDivision of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Naoki SakuyamaDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-2711-1168
Yuichiro TsukadaDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi SasakiDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Yuji NishizawaDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Akinobu TaketomiDepartment of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Masaaki ItoDeparment of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Tetsuya NakatsuraDivision of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-3918-2385

Funding

National Cancer Center Research and Development Fund 25-A-7National Cancer Center Research and Development Fund 28-A-8
6 · The paper itself

Abstract

Chemoradiotherapy (CRT) is the standard neoadjuvant therapy for locally advanced rectal cancer (RC). However, neoadjuvant chemotherapy (NAC) also shows favorable outcomes. Although the immunological environment of RC has been thoroughly discussed, the effect of NAC on it is less clear. Here, we investigated the immunological microenvironment, including T cell infiltration, activation, and topological distribution, of resected RC tissue after neoadjuvant therapies and evaluated the correlation between T cell subsets and patient prognosis. Rectal cancer patients (n = 188) were enrolled and categorized into 3 groups, namely CRT (n = 41), NAC (n = 46), and control (surgery alone; n = 101) groups. Characterization of residual carcinoma cells and T cell subsets in resected tissues was performed using multiplex fluorescence immunohistochemistry. The densities of total and activated (Ki67

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChemoradiotherapyFemaleHumansKi-67 AntigenLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoadjuvant TherapyPrognosisRectal NeoplasmsBiomarkers, TumorKi-67 AntigenMKI67 protein, humanmultiplexed fluorescent immunohistochemistryneoadjuvant chemoradiotherapyneoadjuvant chemotherapyrectal cancertumor-infiltrating lymphocyte

Identifiers

PMID31660687
PMCPMC6942445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.